venBio Partners LLC

Established in 2011, venBio Partners LLC is a life sciences venture capital firm dedicated to investing in innovative biopharmaceutical companies. The firm partners with industry leaders to develop groundbreaking medicines and technologies, emphasizing novel therapeutics for unmet medical needs. venBio's mission is to position its portfolio companies for success by providing strategic guidance and expertise in clinical development.

venBio's investment strategy spans various stages of company development, including seed, early stage, growth, late stage, and pre-IPO. The firm has raised approximately $2 billion in capital commitments and has led investment rounds in over 40 companies. Notable portfolio companies include Labrys Biologics (acquired by Teva), Aragon Pharmaceuticals (acquired by Johnson & Johnson), Seragon Pharmaceuticals (acquired by Roche), Aurinia Pharmaceuticals (NASDAQ: AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Checkmate Pharmaceuticals (NASDAQ: CMPI, acquired by Regeneron), Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS), Akero Therapeutics (NASDAQ: AKRO), Harmony Biosciences (NASDAQ: HRMY), Pharvaris (NASDAQ: PHVS), CinCor Pharma (NASDAQ: CINC, acquired by Astra Zeneca), RayzeBio (NASDAQ: RYZB, acquired by BMS), and many others.

The firm's approach involves taking an active role with each portfolio company, providing strategic guidance on a range of research, clinical, and business activities. venBio seeks opportunities that can deliver meaningful clinical data and value inflection within three to five years, aiming to turn great science into impactful medicine. This collaborative approach has led to the development of approved drugs and significant value creation for both the firm and its partners.